Dynavax (DVAX) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Dynavax Reports First Quarter 2022 Financial Results
May 5, 2022 4:02 PM EDTFirst quarter 2022 total revenue of $114.0 million, up 37% from $83.3 million for Q1 2021HEPLISAV-B® vaccine net product revenue of $20.8 million, up 151% from $8.3 million for Q1 2021CpG 1018® adjuvant net product revenue of $91.5 million, up 23% from $74.6 million for Q1 2021Guidance reiterated for 2022 CpG 1018 revenue, operating expenses, and other costsOn track for a second consecutive year of profitabilityConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., May 5, 2022 /PRNewswire/ --... More
